Stocks · News reference
Grail Exec Says Co. In Conversations With Commercial Payers For Galleri Cancer Test
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
GRAIL Exec Expects Broad Label For Galleri Cancer Test Based On Data Co Has Submitted To FDA
Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
RBC Raises Price Target on GRAIL, Inc.
RBC increased its price target for GRAIL, Inc. to $100 from $84 while maintaining a Sector Perform rating.
GRAIL, Inc. 12-Month Price Target Raised to $134.33
Analysts have increased the 12-month price target for GRAIL, Inc. to $134.33, maintaining a consensus "Buy" rating.